Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312. SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally. The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations. The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy. |
How you could be allergic to your glass of wineJury finds Wisconsin man sane in sexual assault, killing of toddlerUnbeaten but not unbeatable. Roma coach De Rossi believes he has the plan to defeat LeverkusenFord recalls Maverick pickups in US because tail lights can go dark, increasing the risk of a crashFather, 65, earns £85,000Father, 65, earns £85,000Father, 65, earns £85,000Watch where you're going! HeartIndonesia’s Ruang volcano spews more hot clouds after eruption forces closure of schools, airportsWrexham owners Ryan Reynolds and Rob McElhenney want to expand stadium capacity to 55,000